Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the Atlantic Coast Retina Club Macula 20/20 Annual Meeting
–44 week median follow up for patients (n=6)––Zero anti-VEGF rescue injections required following intravitreal ADVM-022; First patient has reached 52-weeks […]
